Inhibitor of Apoptosis Proteins (IAPs) is highly conserved negative regulators of apoptosis overexpressed in many cancer cells. Based on their endogenous antagonist, Smac/DIABLO, mimic compounds (Smac-mimetics, SMs) have been developed to inhibit IAPs prosurvival activity, showing promising effects in advanced phases of clinical trials. Since different IAP homologs play distinctive roles in cancer cell survival and immunomodulation, SMinduced apoptosis proceeds through diverse mechanisms. After binding to their BIR3 domain, SMs have been shown to rapidly induce auto-ubiquitylation and degradation of cellular IAPs (cIAPs), thus leading to cell death mainly by activation of the noncanonical NF-jB pathway. For this reason, we started the BIR3-driven design of compounds selective for cIAP1 and with reduced affinity for X-linked IAP (XIAP), in order to focus SMs antitumor activity on cIAPs degradation. In this work, we describe the crystal structures of the BIR3 domains of cIAP1 and XIAP, each in complex with a cIAP1-selective SM (SM130 and SM114, respectively). The two SMs displayed 23-and 32-fold higher affinity for cIAP1-BIR3 over XIAP-BIR3 in molecular displacement experiments based on fluorescence polarization. In vitro cell-based assays confirmed that both selective SMs triggered apoptosis in cancer cells with different efficiencies by inducing caspases-3, -8, and -9-independent cIAP1 degradation. The design of cIAPs-selective compounds represents an innovative approach in the field of anticancer drugs development, being useful to elucidate different prosurvival mechanisms and to reduce the adverse effects of pan-IAPs compounds in cancer therapy.
Introduction
Inhibitor of Apoptosis Proteins (IAPs) are overexpressed in many cancer cells, being involved in cancer onset and progression [1, 2] . The IAPs family includes a variety of members able to inhibit apoptosis in different manners. Furthermore, IAPs participate in inflammatory responses, thus representing optimal targets also for immunomodulation [3, 4] . During apoptosis, one of the most representative IAPs members, XIAP (X chromosome-linked IAP), directly inhibits effector caspases 3 and 7 and initiator caspase 9, preventing their proteolytic cleavage and activation [5] , whereas cIAPs (cellular IAPs) are crucial players of the NF-kB survival pathway. IAPs are composed of one to three BIR (Baculoviral IAP Repeat) domains of approximately 70 amino acids, which promote the interactions with molecular partners. BIRs contain a zinc-finger motif and are classified in Type I (namely BIR1) and II (namely BIR2 and BIR3) according to the absence/presence of a specific IBM (IAP-binding Motif) groove. More in detail, type I BIRs mediate cIAPs recruitment to the TNFRSC (Tumor Necrosis Factor-a Receptor Signaling Complex), whereas type II BIRs are responsible for direct inhibition of caspases [6] . BIRs are followed by an UBA (Ubiquitinassociated) domain, involved in the binding of ubiquitin and in signaling processes. A RING (Really Interesting New Gene) domain is present at the C terminus, promoting IAPs dimerization and/or IAPs E3 ligase activity [7] . cIAPs also contain a CARD domain (Caspases activation and Recruitment Domain) [1, 8] . A successful approach to inhibit IAPs is based on the design of small molecules mimicking the endogenous IAP antagonist Smac/DIABLO (Second mitochondriaderived activator of caspases/Direct IAp-binding protein with Low pI) [9] [10] [11] [12] [13] [14] [15] [16] [17] and some of these Smacmimetics (SMs) are now in advanced phases of clinical trials [18, 19] . SMs target the IBM groove on IAPs located in the type II BIR domains, and in particular in the BIR3 domain (residues 265-330 in XIAP, 269-336 in cIAP1, 255-322 in cIAP2). Even if they have been originally designed to prevent XIAP binding to caspases, SMs' proapoptotic activity is mainly due to cIAPs auto-ubiquitylation and degradation that activate the extrinsic apoptotic pathway. Sun et al. [20] designed a set of potent SMs selective for cIAPs, showing that XIAP-BIR3 targeting is not required for effective induction of apoptosis in selected tumor cells. On the contrary, XIAP anti-apoptotic role is essential in tumor cell lines [21, 22] , during mitotic cell death [23] or during inhibition of NF-kB pathway via XIAP interaction with TAB 1 [24, 25] . In this context, the study of SMs selective for different IAPs would be useful for (a) elucidating the role of homologous IAPs in different cancer cells and (b) improving the tolerability of SMs in cancer treatments [9] .
The binding of Smac/DIABLO is about sevenfold stronger for cIAP1/2 (85 AE 8 nM [26] ) than for XIAP (0.58 AE 0.15 lM [27] ). Accordingly, SMs often display greater affinity for cIAPs-than for XIAP-BIR3 [10, 28, 29] . To enhance such natural selectivity using a structure-based approach, we designed SM114 and SM130. In this work, we report the crystal structures of XIAP-BIR3 in complex with SM114 and of cIAP1-BIR3 in complex with SM130, showing the structural determinants crucial for the preferential binding of both SMs and cIAP1. Our results are further supported by the biochemical and biophysical characterization of SM114 and SM130 binding to the different BIR3 domains. Finally, cell-based assays show that both the cIAP1-selective SMs here reported induce tumor cell death in a caspases-independent manner, that is, targeting cIAP and not XIAP.
Results

Structure-driven design of SM114 and SM130
SM compounds are based on the N-terminal tetrapeptide of Smac/DIABLO (Fig. 1A , top left). Starting from Smac005 (Fig. 1A , top center) [30] , we (a) added a methyl group at the ammine of P1 to enhance bioavailability [27, 31] and (b) removed one phenyl group in P4 [30] , producing SM5 m (Fig. 1, top right) .
The sequence alignment of the BIR3 domains from homologous IAPs members (XIAP, cIAP1, and cIAP2) reveals some amino acid substitutions in the SM-binding pocket (Fig. 1B) . Among the residues which usually interact with SMs, XIAP Leu292 is substituted with the smaller amino acid Val in cIAPs, thus suggesting the addition of a bulkier tert-butyl group in the P4 position of SM5 m (Fig. 1A, compound SM114 ) to favor the affinity for cIAPs. Furthermore, considering that XIAP Asp309 is substituted with cIAP1 Cys, we modified SM5 m central scaffold with an a,b-unsaturated group to promote the formation of a covalent Michael adduct on the -SH group of Cys (Fig. 1A, compound SM130 ).
Structural bases of SMs selectivity vs cIAP1: virtual docking
The binding modes of SM114 and SM130 on XIAPand cIAP1-BIR3 were first analyzed in silico using virtual docking. As expected, both molecules show higher affinity for cIAP1-respect to XIAP-BIR3. SM114 tertbutyl group in SM114 displays three different orientations in XIAP-BIR3: one close to the protein (DG = À9.3 kcalÁmol À1 , estimated inhibition constant, k i = 141 nM) and the other two oriented toward the solvent (DG = À7.9, À7.7 kcalÁmol À1 ). Conversely, in cIAP1-BIR3, the SM114 tert-butyl group binds to the larger hydrophobic cleft due to Ile292Val substitution (DG = À10.2 kcalÁmol À1 ; k i = 35 nM).
Since virtual docking does not consider the energy gained after the formation of a covalent bond, the SM130 in silico affinity for cIAP1-BIR3 is underestimated. Nevertheless, SM130 displays a higher affinity for cIAP1-BIR3 (DG of À10.6 kcalÁmol À1 ; k i = 17 nM) then for XIAP-BIR3 (DG of À9.4 kcalÁmol À1 ;
SM130 forms an intramolecular covalent bond with cIAP1-BIR3 in solution
The formation of the covalent bond between SM130 and cIAP1-BIR3 was assessed through mass spectrometry (MALDI-TOF) and SDS/PAGE, comparing samples of cIAP1-BIR3 purified by size exclusion chromatography (SEC) in the absence/presence of SM130. The elution profiles of cIAP1-BIR3 with/ without SM130 (3 h incubation) remains the same (V E = 17.9 mL; calculated Mw = 14.3 kDa; Fig. 2A ). Accordingly, dynamic light scattering data show that both the apoprotein and the protein complex with SM130 (polydispersity < 20%) [32] display a hydrodynamic radius corresponding to their monomeric forms (2.1 AE 0.1 nm for cIAP1-BIR3 and 2.0 AE 0.1 nm for the complex). MS analysis shows that, after 3 h of incubation with SM130, the cIAP1-BIR3 peak (m/z 14343, Fig. 2C ) is substituted by the peak of the covalent adduct (m/z 14817; Fig. 2D ). The formation of a covalent bond was also evident in electrophoretic experiments under denaturing conditions, where, in the case of the cIAP1-BIR3/SM130 complex purified by SEC, we observed a band shift toward higher MW (not present with SM114; Fig. 2B ). The band shift does not occur in the case of XIAP-BIR3/SM130 (Fig. 2B ) despite the exposed Cys351 in a5 helix (solvent accessible area = 91 AE 11 A 2 averaged over the eight molecules in a.u.).
Beside Cys309 (solvent accessible area = 86 A 2 ), cIAP1-BIR3 hosts four Cys residues. Excluding a covalent bond of with the zinc-finger Cys (Cys299, Cys303, and Cys327) that would led to protein unfolding, or with the buried Cys302 (accessible surface area of 17 A 2 ), we are confident that SM130 can establishes a covalent bond only with Cys309 in the IBM groove. Determination of SM114 and SM130 affinity toward XIAP-and cIAPs-BIR3: indirect and direct measurements of selectivity During fluorescent polarization (FP) assays, we measure the emission of a fluorescent SM [30, 33] when displaced by SM114 or SM130. SM114 display about 23-fold higher affinity for cIAP1-BIR3 over XIAP-BIR3 (EC 50 = 345.1 nM and 7903.0 nM, respectively; Table 1 ). In the same way, SM130 displays a 32-fold higher affinity for cIAP1-BIR3 (EC 50 = 9.7 nM) over XIAP-BIR3 (EC 50 = 306.6 nM).
These results are in agreement with thermal stability assays, measuring the stabilizing effects induced by the SMs on the different BIR3 domains. SM114, incubated for 30 min or 3 h with the proteins, induces a thermal stabilization of 18.2 AE 0.4°C and of 13.1 AE 0.1°C for cIAP1-BIR3 and XIAP-BIR3, respectively ( Table 1) . As expected, due to the formation of a covalent bond, a greater thermal stabilization is observed after 3 h of incubation for SM130 with cIAP1-BIR3 (DT M = +36.0 AE 0.1°C vs 23.5 AE 0.3°C after 30 min), but not with XIAP-BIR3 (DT M = 24.6 AE 0.2°C; Table 1 ).
Structural bases of selectivity: X-ray crystal structures
XIAP-BIR3/SM114 structure
The crystal structure of XIAP-BIR3/SM114 shows eight protein domains per asymmetric unit, identified by chain IDs A-H (modeled amino acid ranges 254 (AE1)-353(AE2)). Around each IAP-binding motif (IBM) groove, the residual electron density allowed to model one molecule of SM114 between strand b3 and helix a3.
The superimposition of the eight molecules in the asymmetric unit shows that overall SM114 maintains the typical interaction network of SMs (Fig. 3, Table 2 ) [10, 11, 30, 33] . Conversely, as observed in virtual docking, the tert-butyl group assumes different orientations within the IBM groove (Fig. 3) being directed toward the Leu292 hydrophobic cleft (average distance 3.7 AE 0.3 A) in five molecules (chains A, B, D, F, and H), and pointing toward the solvent or toward symmetry-related molecules in the remaining three molecules (chains C, E, and G). Accordingly, SM114 displays slightly higher average B factor values (B = 81 AE 21 A
2 ) compared to that observed for BIR3 (B = 74 AE 8 A 2 ). Taken together, the structural data indicate that SM114 interaction with Leu292 cleft is unfavorable, determining the reduced affinity for the XIAP-BIR3.
cIAP1-BIR3/SM130 structure
The crystal structure of cIAP1-BIR3/SM130 shows two protein domains per asymmetric unit forming a symmetric dimer, with the two IBM grooves facing a twofold rotation axis (Fig. 4) . The refined model lacks the first 12 N-terminal residues (241-253) and the last two C-terminal residues. SM130 is located between b3 and a3 (Fig. 4A) , stabilized by the typical BIR3/SM interactions (Fig. 4B , Table 2 ). Interestingly, during the refinement, we identified a residual electron density between the SM130 4-enone group and the Cys309 of the opposite cIAP1-BIR3 molecule (Fig. 3B ), allowing to model a covalent bond (C-S distance 1.8
A). The analysis of protein interfaces with PISA (proteins, interfaces, structures, and assemblies http://www.eb i.ac.uk/pdbe/pisa/) suggests that the crystallographic dimer is probably not maintained outside the crystal. Interestingly, the crystal packing is unique among all the known structures of cIAP1-BIR3, suggesting that it could be due to the formation of the covalent bond.
SM130 induces apoptosis in MDA-MB231 cancer cells more efficiently than SM114
The ability of SM114 and SM130 to induce apoptosis was tested in MDA-MB231 cells in which caspases-3, -8, and -9 were silenced (Fig. 5A ). As expected, the treatment with SM114 and SM130 triggers the degradation of cIAP1 independently from the silencing of caspases, suggesting a direct effect of the compounds rather than a consequence of caspase activation. However, SM130 reduces the levels of cIAP1 more efficiently and an increased cleavage of PARP is observed (Fig. 5A, left panel) , hence supporting the idea that SM130 is endowed with an increased pro-apoptotic activity compared to SM114. To test this hypothesis, we performed a cell viability assay with MDA-MB231 cells, pretreated or not with the pan-caspases inhibitor Z-VAD, and treated with SM130 or SM114. As shown in Fig. 5B ; both SMs induce cell death, which is prevented by Z-VAD, thus indicating a caspase-dependent apoptosis process. Nonetheless, EC50 values (2.5 lM for SM130 and 18.2 lM for SM114) confirm that SM130 triggers apoptosis more efficiently then SM114. Remarkably, the strong reduction of PARP cleavage, which is detected in cells treated with SM130 and depleted for caspase-8 ( Fig. 5A left panel) , suggests that SM130 mainly activates the extrinsic apoptotic pathway.
Discussion
Research on SMs led to the identification of several drugs currently in clinical trials. SMs are pan IAP inhibitors; nevertheless, an approach to target selectively a subset of IAPs, in order to elucidate their role in apoptosis modulation, is needed. Here, we described a structure-based approach for the design of selective SMs, able to discriminate between cIAPs and XIAP.
We started from the analysis of the IBM in different BIR3 domains identifying two amino acid substitutions in position 292 and 309, whose structural features could be useful to produce selectivity. We then synthesized two SMs, SM114 exploiting position 292 and SM130 exploiting position 309, both predicted to have higher affinity for cIAP respect to XIAP. We experimentally tested our hypothesis demonstrating the higher affinity for isolated BIR3 domains by 23-(SM114) and 32-(SM130) fold, respectively. Furthermore, in vitro cell-based assays revealed that both SM114 and SM130 are able to induce apoptosis in MDA-MB231 cells, like other SMs belonging to our library [16, 20, 34] . Finally, SMs selectivity was confirmed by the caspase-independent autodegradation of cIAPs. However, SM130 results to be a more potent proapoptotic compound compared to SM114, inducing efficient PARP cleavage, and exhibiting a lower EC50 value (2.5 lM vs 18.2 lM for SM114) in cell viability assay. This effect is probably due to the SM130 higher affinity for cIAP1-BIR3, also due to the formation of a covalent bond with Cys309.
The use of covalently bound/irreversible drugs is not uncommon: to give few examples, the anticancer drug, proteasome inhibitor bortezomib [35] or the gastric drug, proton pump inhibitor omeprazole [36] . In recent years, the number of drug candidates with a covalent mechanism of action progressing through clinical trials or being approved by the FDA has grown significantly [37] [38] [39] . As interest in covalent inhibitors has increased, the technical challenges for characterizing and optimizing these inhibitors have become evident. Here, we demonstrated that SM130, the first SM covalently binding to cIAP-BIR3, maintains the typical SM-binding mode, showing greater affinity vs cIAPs over XIAP. In particular, experimental evidences suggest that SM130 is able to form a covalent bond with the cIAP1-BIR3 protein. Furthermore, SM130 even if it is able to bind effectively to XIAP-BIR3 is not able to form nonspecific covalent bonds with this protein, suggesting that its overall toxicity due to the presence of a reactive group could be limited. Nevertheless, at this stage of the research, possible SM130 side effects cannot be ruled out. In comparison with other SMs, the effect of the covalent bond could result in favorable kinetics and highly persistent pharmacological effects, which need to be further investigated. In general, the development of new SMs selective for cIAPs could reduce some of the side effects due to the inflammatory response associated with the strong inhibition of XIAP [9] . Finally, selective SMs could target tumors whose onset or progression depends on different cellular processes involving diverse IAP homologs.
Materials and methods
SM114 synthesis
SM114 (Fig. 1 , bottom left) was prepared similarly as described for alcohol Smac005/7b [15] . Namely, the same synthetic protocol (five steps, (i) to (v), Scheme 1 in [20] ), was followed, just replacing in step (v) benzhydrylamine Ph 2 CHNH 2 with (p-t-butyl)-benzylamine (4-t-BuPh) CH 2 NH 2 . Then, N-Boc-protected SM114 (50 mg, 0.088 mmol) was dissolved in MeOH (6 mL) and deprotected using methanolic 3N HCl (1.5 mL, 4.5 mM). The reaction mixture was stirred at room temperature for 2 h, while monitoring by TLC. Then, the solvent was removed under reduced pressure. 
SM130 synthesis
SM130 (Fig. 1 , bottom right) was prepared similarly as described for amine Smac067/9a [15] . Namely, the same synthetic protocol (eight steps, (i) to (viii), Scheme 1 in [20] ), was followed, just replacing benzhydrylamine Ph 2 CHNH 2 with benzylamine PhCH 2 NH 2 in step (v) to provide the N-Boc benzylamidoamine analog Boc-NBn-Smac67 (Scheme S2 Cell viability was assessed after 72 h. Graphs are averages (AE SEM) of three independent experiments (n = 3). Statistical significance of differences was evaluated by paired t test (*P < 0.05; **P < 0.01; ***P < 0.001).
CH 2 Cl 2 to 10% MeOH/90% CH 2 Cl 2 ). Yield: 78% (89 mg, MW 569.7, 0.0156 mmol) of a pure amorphous white solid. N-Boc-protected SM130 (80 mg, 0.14 mmol) was dissolved in MeOH (10 mL) and deprotected using methanolic 3N HCl (2.5 mL, 7.5 mmol). The reaction mixture was stirred at room temperature for 2 h, while monitoring by TLC. Then, the solvent was removed under reduced pressure. The crude solid was purified by reverse semipreparative HPLC (C18 column), and then lyophilized to yield the pure hydrochloric salt of SM130 (43 mg In silico docking
AutoDock4 [40] was used for virtual docking analysis and Python Molecule Viewer 1.4.5 to analyze data. Molecule A in cIAP1-BIR3/Smac037 (PDB ID: 3MUP [33] ) structure deprived of the SM, with hydrogen atoms and Kollman charges, was used to perform virtual docking searches around amino acid 308; 52 grid points were chosen in all dimensions (148 877 total grid points per map), with a separation of 0.375 A, resulting in a cubic box of (21 A) 3 . During the docking simulation, the protein was constrained as rigid, whereas the SMs were free to move. The docking was computed with 50 independent genetic algorithm (GA) runs.
Protein expression, purification, and crystallization
The protein constructs of XIAP-and cIAP1-BIR3 were expressed and purified as reported [30] [33] . For the complexes cIAP1-BIR3/SM130 and XIAP-BIR3/SM114, sitting drop crystallization experiments were prepared using an Oryx-8 crystallization robot (Douglas Instruments, East Garston, UK), from a 2:1 mixture of the protein stock solution (1 mM protein in 50 mM Tris-HCl pH 7.5, 200 mM NaCl, 10 mM DTT) with 5 mM of SMs, and the precipitant solution to a final drop volume of 0.3 lL for the initial screenings and of 0.5 lL for the optimization trials. Elongated prismatic crystals were observed for cIAP1-BIR3/ SM130 complex after 1 week at 20°C in the presence of 12% PEG 3350, 0.1 M BisTris pH 5.9, 0.22 M MgCl 2 . Cubic crystals of XIAP-BIR3/SM114 complex grew after 2 weeks at 20°C in the presence of 10% PEG 400, 0.1 M Hepes-Na pH 7.5, 0.2 M MgCl 2 . Crystals were soaked in a cryoprotectant solution containing the precipitants together with 20% glycerol and 5 mM SMs before being fresh-cooled in liquid nitrogen for data collection.
Structure determination and refinement
The crystals of cIAP1-BIR3/SM130 and XIAP-BIR3/SM114 diffracted to a maximum resolution of 2.2 and 2.7
A, respectively, using synchrotron radiation on beam-line ID23-1 at the European Synchrotron Radiation Facility (ESRF-Grenoble, France). The diffraction data were processed with MOSFLM [41] , and intensities were merged using SCALA [42] . The cIAP1-BIR3/SM130 crystal belongs to the P3 2 21 space group with unit cell parameters a = b = 53. 8 A, c = 176.6 A, and two molecules in the crystal asymmetric unit (52.0% solvent content [43] ). The XIAP-BIR3/SM114 crystal belongs to the P2 1 2 1 2 1 space group with unit cell parameters a = 57. 2 A, b = 97.1 A, c = 182.6 A, and eight molecules in the crystal asymmetric unit (45.6% solvent content). The crystal structures were solved by molecular replacement [44] , using as search models the structures of cIAP1-BIR3/Smac037 complex (PDB code 3MUP [33] ) and of XIAP-BIR3/Smac005 complex (PDB code 3CLX [30] ), respectively. The independent molecules were subjected to rigid body and restrained refinement using REFMAC5 [45] . A random set comprising 5% of the data was omitted from refinement for R-free calculation. Inspection of difference Fourier maps at this stage showed strong residual density, located between the a3 helix and the main b-sheet, compatible with one SM inhibitor bound to each molecule in the asymmetric unit that was accordingly modeled. Manual rebuilding [46] and additional refinement [47] were subsequently performed to final R factor/ R-free values of 19.4/25.1% and 26.8/34.4%, respectively. The stereochemical quality of the models was checked using the program Procheck [48] and is summarized in Table 3 , together with data collection and refinement statistics. Protein interfaces and assemblies were analyzed with the package PISA (http://www.ebi.ac.uk/pdbe/pisa/). Atomic coordinates and structure factors for cIAP1-BIR3/SM130 and XIAP-BIR3/ SM114 complexes have been deposited with the Protein Data Bank [49] with accession codes 6EXW and 6EY2, respectively.
Fluorescence polarization and melting temperature shift assays
Fluorescent polarization experiments and melting temperature shift assays were performed as reported [30] and [33] . Briefly, SMs were incubated with the proteins for 3 h prior FP and for 30 0 or for 3 h prior the melting temperature shift experiments. Melting temperature shift assays were conducted in triplicates and the average values together with standard errors were used to calculate the DT M . The FP EC 50 values are shown in Table 1 together with the T M values obtained for XIAP-and cIAP1-BIR3 alone (concentration of 30 lM) and in the presence of 2 mM SMs.
Dynamic light scattering and size exclusion chromatography
The purified proteins were centrifuged at 13 000 g for 10 min prior to DLS analysis; the measurements were carried over at 10°C in a DynaPro instrument (ProteinSolutions, Charlottesville, VA, USA) using a protein concentration of 2 mgÁmL À1 (140 lM) and 2 mM of the SM. Size exclusion chromatography was performed on a Superdex TM 200 10/300 GL increase (GE Healthcare S.r.l., Milan, Italy) in 50 mM Tris-HCl pH 7.5, 200 mM NaCl, 5 mM DTT.
Mass spectrometry analysis
Matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry was performed using a Microflex Lt Bruker Daltonics by Brucker, equipped with a pulsed ion extraction analyzer, 120 cm linear flight path, and 701 s À1 turbo molecular pump, with backing pump.
The sample observation optics comprised of a 337 nm nitrogen laser with computerized attenuation and positive ion analysis at 20 kV acceleration. The calibration was performed by means of a peptide mixture with molecular weight below 20 000, purchased from Brucker. The samples were prepared by the dried droplet technique, using a-hydroxycinnamic acid (HCCA) as the matrix, according to the following procedure: 0.30 mg of each solutions A1 and A2 was dissolved in 1 mL of water. Solution B: 10 mg of a-hydroxy cynnamic acid (HCCA) was dissolved in 1 mL of 80:20 water acetonitrile solution. Solutions A1 and A2 (1 mL each) were separately mixed with solution B (1 mL) and the resulting solutions were cast on the stainless scout and dried at room temperature.
Cell line and drug treatments
The MDA-MB231 cell line was obtained from ATCC and cultured in mycoplasma-free conditions in RPMI-1640 supplemented with 10% FBS, 2 mM L-glutamine, 10 mM HEPES buffer, 0.1 mM nonessential amino acids, and 1 mM sodium pyruvate (all from Lonza, distributed by Euroclone, Pero, Italy). SM130 and SM114 were incubated for 24 h at 1 lM final concentration to assess cIAP1 degradation while for the cell viability assay different SM concentrations, ranging from 0.01 to 50 lM, were tested for 72 h. Z-VAD(OMe)-FMK was purchased by BIOMOL and added 1 h before treatment with SMs at 20 lM final concentration.
Transfection
Cells were transiently knocked down following a reverse transfection protocol employing siRNAs (Dharmacon) and RNAiMAX reagent (Thermo Fisher Scientific, Rodano, Italy) as already reported [50] .
Western blot
Cells detached with Trypsin-EDTA solution (LONZA, distributed by Euroclone) were harvested by centrifugation, 
Cell viability assay
Cell viability assay was tested by seeding MDA-MB231 cells (10 4 cells/well) in 96 well plates. Cells were treated with the described SMs and viability determined 72 h later by CellTiter-Glo (Promega, Milan, Italy).
